-
Effect of hematopoietic stem cell transplantation on the long-term prognosis of CD30+ PTCL patients receiving vebutuximab in combination with CHP first-line
Time of Update: 2022-12-04
The randomized, double-blind phase 3 ECHELON-2 study (NCT01777152) showed that first-line vebutuximab combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) significantly improved progression-free survival (PFS), overall survival (OS), complete response (CR), and overall response rate (ORR) in patients with CD30+ PTCL compared with traditional CHOP regimens, with 。 As first-line therapy improves, the role of HSCT consolidation therapy also needs to be reassessed.
-
Professor Hao Chunyi: Bioequivalence ≠ clinical equivalence, and the clinical efficacy of lenvatinib generic drugs must be verified
Time of Update: 2022-12-04
*For medical professionals onlyLiver cancer targeting and immunotherapy drugs are fundamentally subverting the treatment concept and clinical practice of advanced hepatocellular carcinoma (HCC), and 2
-
Hot News Doesn't cost money but is effective? Prostate cancer patients move!
Time of Update: 2022-12-04
Figure 1 Cytokine data analysis>>>>Conclusion of the studyPerioperative yoga exercises improve QoL, enhance anti-cancer immune response, and reduce inflammation in patients with PCa. Further research is needed on the mechanism of yoga to improve QoL and its effect on PCa progression and recurrence in the future.
-
The 2022 CSCO | Intensive Study, Innovative Drug Clinical Research Data Session 2 was successfully held in the cloud
Time of Update: 2022-12-04
5Professor Chen Zhendong: Safety safety, tolerability and preliminary antitumor activity of seltratinib combined with tislelizumab in patients with locally progressed unresectable or metastatic gastric cancer and gastroesophageal junction cancerThis is an open-label, multicenter, non-randomized, multi-cohort phase II clinical trial (NCT03941873).
-
Micro-classroom No. 17 Professor Zeping Zhou: The value of MRD detection in multiple myeloma
Time of Update: 2022-12-04
In recent years, the continuous emergence of new drugs and the improvement of detection methods have made the treatment of multiple myeloma (MM) more effective, the past efficacy evaluation standards
-
2022 CSCO Neurological Tumor Session Return, teniposide return to chemotherapy prescription
Time of Update: 2022-12-04
Professor Mo Ligen, a speaker at the discussion session of Professor Fan Cungang, said that he expects electric field therapy to be included in medical insurance as soon as possible, improve accessibility, and bring clear clinical benefits to glioma patients 。 In addition, Professor Morligan mentioned that teniposide has shown good efficacy in the treatment of brain glioma and brain metastases of various malignant tumors, and looks forward to continuing to carry out large-scale phase III.
-
4 magic weapons for precise combat of prostate cancer, Professor Ye Dingwei shared Fudan tumor experience
Time of Update: 2022-12-04
Professor Ye Dingwei delivered a report at the CSCO conference, Professor Ye introduced that the development direction of prostate cancer diagnosis and treatment in China is mainly precision strike + joint victory, in order to carry out precise blows on prostate cancer, it is necessary to start from four aspects:Precise screening for prostate cancer;Precise staging;Precise molecular typing;Precise surgery should be carried out for early prostate cancer, and symptomatic measures should be implemented for intermediate and advanced prostate cancer.
-
The Return of the King coincides with its "suitable" | teicolarin (Tagshi) ® expert seminar/the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2022-12-04
Patients with blood diseases often cause neutropenia and impaired immune function due to the disease itself or treatment measures such as chemotherapy, and are a high-risk group for infection. Therefo
-
S100A4 is a potential target for immunotherapy for human glioma
Time of Update: 2022-12-04
Conclusion of the study In summary, the authors' comprehensive analysis of 201,986 human gliomas, immune cells, and other stromal cells at the single-cell level revealed extensive spatial and molecular heterogeneity in immune infiltration.
-
Posterior median resection of the infraphysipital pathway of the boneless window has fossa lesions after resection
Time of Update: 2022-11-26
David Pitskhelauri, Department of Neuro-Oncology, Burdenko National Neurosurgical Medical Research Center, Ministry of Health of the Russian Federation, introduced the experience of transatlanitipita
-
European Radiology: The value of three-dimensional gradient echo sequence reconstruction images based on compressed sensing in the diagnosis of jaw cancer
Time of Update: 2022-11-26
BI-1, which is not osteoinvasive or limited to cortical bone; BI-2, invasion of cancellous bone is observed, but does not extend to the mandibular canal (MC); BI-3, the scope of the violation extends to the MC This study shows that the reconstructed CS-3D-T1TFE image has important clinical value for the diagnosis of mandibular cancer.
-
Professor Shao Zhimin's interview| pembrolizumab was approved for a new indication in China, entering a new era of treatment for early triple-negative breast cancer
Time of Update: 2022-11-26
It is reported that Merck's blockbuster product pembrolizumab injection (Keytruda, Keytruda ® The new indication was recently approved by China's National Medical Products Administration (NMPA), which is the 10th indication approved in China since pembrolizumab was first approved in China in 2018; This approval makes pembrolizumab the first and only immune checkpoint inhibitor in China for early high-risk triple-negative breast cancer (TNBC) in combination chemotherapy in the adjuvant stage, which will change the treatment pattern of patients with early TNBC.
-
Microdissection of insular leaf and insular fiber bundle
Time of Update: 2022-11-26
[Epub ahead of print] 】 Research background The insular leaf is surrounded by the island cover, and there are many important white matter fiber bundles running deep on the insular leaf.
-
2022 CSCO Professor Chen Yongyi: Real-world studies have confirmed that triracillide can improve chemotherapy-induced myelosuppression in different ES-SCLC patients
Time of Update: 2022-11-26
This CSCO Annual Meeting includes a real-world study evaluating the protective effects of triraciclib in myelosuppressive protection induced by chemotherapy in patients with extensive small cell lung cancer (ES-SCLC) in China.
-
Summary of NCCN Clinical Practice Guidelines Chinese (October 2022)
Time of Update: 2022-11-25
5 Edition (2) (Chinese)NCCNClinical Practice Guidelines for Non-small Cell Lung Cancer 2022.
5 Edition (2) (Chinese)NCCNClinical Practice Guidelines for Non-small Cell Lung Cancer 2022.
5 Edition (2) (Chinese)NCCNClinical Practice Guidelines for Non-small Cell Lung Cancer 2022.
-
European Radiolog: Clinical value of non-contrast VI-RADS in evaluating muscle invasion in bladder cancer
Time of Update: 2022-11-25
AUC, area under the curve; DCEI, dynamic contrast-enhanced imaging; DWI, diffusion-weighted imaging; ROC, receiver work characteristics; T2WI, T2 weighted imaging; VI-RADS, Bladder Imaging Reporting and Data SystemIn this prospective study using a 3T HG MRI scanner, the predictive accuracy of NCE-VI-RADS for muscle invasion in bladder cancer was comparable to that of conventional VI-RADS.
-
The first FRα-ADC drug has been approved by the FDA for the accelerated treatment of refractory ovarian cancer
Time of Update: 2022-11-25
Its constituent structure is composed of a chimeric antibody IgG1 targeting CD30 coupled to the tubulin inhibitor MMAE through a protease-sensitive linker, Vat-Cit. The drug is mainly suitable for classical Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (sALCL), and was approved by NMPA in 2020 for the treatment of patients with relapsed or refractory sALCL and CD30-positive HL, and is the second ADC approved for marketing in China.
-
eClinicalMed: Efficacy of RNA oligonucleotide STNM01 in the second-line treatment of chemotherapy-refractory pancreatic cancer
Time of Update: 2022-11-25
Changes in tumor-infiltrating immune cells A total of 22 patients were enrolled, with a maximum of 3 courses of treatment; No dose-limiting toxicity was observed.
Changes in tumor-infiltrating immune cells A total of 22 patients were enrolled, with a maximum of 3 courses of treatment; No dose-limiting toxicity was observed.
-
European Radiology: Bone Density Can Predict the Prognosis of Elderly Liver Cancer Patients Treated with TACE!
Time of Update: 2022-11-25
Based on Child-Pugh and ALBI scores, the distribution of bone mineral density (BMD) in different (A) Child-Pugh stages and (B) ALBI scoring stages was figured This study shows that low BMD is an independent predictor of survival in elderly HCC patients receiving TACE.
-
European Radiology: Application of DTI in the identification of benign and malignant liver lesions
Time of Update: 2022-11-25
47, respectively This study shows that MD and FA derived from diffusion tensor imaging are two non-invasive, reliable, and reproducible imaging indicators, and are superior to ADCs measured by conventional DWI, and can be used for the differential diagnosis of benign liver focal lesions.
